SRNE..Opened today 8.15..Up 20% 9.60 Rose on news this morning..H.C. Wainwright analyst Ram Selvarajo raised Target Price from 25.00 to 30.00..Sorrento has a stake in two cell-based immunotherapy companies..One is Celurarity which is going public later this year merging with GX Acquisition Corp.Equity value will be $1.7 Billion..Sorrento's position might be worth $200 Million..Sorrento already has two rapid detection tests .. Return on Equity projected to be 320% Return on Assets 109% Revenue Forecast to grow 257% Market Cap 2.655 Billion Held by 267 Institutions with 33% of shares
OCGN...2.20 India Starts Vaccinating its 1.3 Billion People Covishiels Vaccine developed by Astrazeneca and Oxford University and Covaxin developed by Bharat Biotech of India were authorized for emergency use in India.. On December 22nd Ocugen signed binding letter of intent with Bharat Biotech to co-develop the Vaccine.Letter of intent calls for Ocugen to get the US rights to the Vaccine Candidate and in collaboration with Bharat be responsible for clinical development, registration and commercialization for the US Market. Covaxin has garnered interest from Countries Worldwide. Ocugen's foray into Covid-19 Vaccine will not delay work on it's gene-based therapies for retinal disorders.
Should I stay or should I go..Will it go High or will I see it down Low SRNE..9.50..Sorrento Therapeutics on Friday UP 18% on four times the volume..Generated by a raise in Target Price from 25.00 to 30.00 I can look at this as half-empty..blah..blah..blah..i have a better chance of regrowing hair than this has of hitting 30.00 But the half-full side of me has down some research and Sorrento has quite a loaded pipeline. Drugs in four categories..Covid..Cancer..Pain and Lymphatic.. Covid they have two drugs in FDA Emergency use..One completed Clinical Trials..One in Phase 1 and One in Phase 2 Cancer One pre-clinical..Four in Phase 1..one in Phase 2 and One in Phase 3 Pain Two in Phase 2 Lymphatic Two in Phase 1 So in conclusion board the Train for Unknown Destination.
NCNA..7.00 Up 7% Friday.. Nucana a Clinical-Stage Bio-Pharm focused on improving treatment outcomes for patients with cancer. Friday positive results on three-part study of NUC-3373 synthase inhibitor for patients with collerectal cancer..Also in Phase3 Acelerin a treatment for binary tract cancer. Market Cap...358 Million..Float Low 24 Million Short term assets $146 Million exceed Short term liabilities of $11Million and Long term liabilties of $600K Cash and Cash Investments of $129Million ..A Cash Burn $28Million StockTA Bullish Long Financhill scores a Buy with a 98 out of 100 Four Analysts rate Buys with Median Target Price of 17.33
News out this morning from Spain GRFS..19.08 Grifols will begin Clinical Trials of new treatment that would provide immediate immunity against Covid-19..Treatment can be admistered in Primary Care Centers to avoid Hospitalization..The Medicne would provide immediate protection after exposure of the Virus. Market Cap 17.4 Billion..Owned by 239 Institutions holding 47% of stock Although Short term assets exceed Short term liabilities..Long term liabilities exceed Short term assets. A positive Cash on hand $2.7 Billion exceeds Cash Burn of $169 MillionRevenue growth 47% Median Target Price of 34.00
OBSV..Bio-Pharm therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Up 18% pre-market..4.80 Market Cap 223 million..Float 37 million Short term assets exceed both Short and Long term liabilities. Debt 26 million Assets 84 million Three drugs in pipeline..One in Phase 3..One in Phase 2 and One in pre-clinical StockTA Bullish Short and Long Median Target Price 8.00
DBVT..Profiled last week Up again pre-market 35% 7.60 News late last week on success of peanut allergy patch
INUV..Up 50% pre-market to 1.00 Developes and sells IT Solution Info based on previous close Projected to rise 43%..holding .66-1.00 Debt now only 2.34 Million...Assets 35.2 Million When this settles down this morning a Strong Buy
AVGR..Up 30% Friday to 1.47..Ticking up this morning 1.51 Buy and Hold Recommedation Catheter devices to treat vascular diseases Friday release of Tigereye Catheter Device which allows physicians to see inside artery in real-time Short term assets exceed both Short and Long term liabilities Cash now 25 million Cash Burn 15 million Debt 16 million Assets 36 million Also staying up pre-market CRNT..Up 100%..Wireless Backhaul solutions..Low Float 58 million..Debt 17 million with Assets of 273 million NDRA Up 30% 1.37..Granted US Patent last week
ADMA..Up 15% this morning 2.34 News just out on earnings..4th quarter of 2020 13.9 million the best quarter ever since Company's inception. 2020 Revenue 42 million a 44% increase from 2019
One to watch LIXT..Up today 3.53 Just received approval to start Phase 1 Clinical Trial of their Lung Cancer Drug Fair Bid 3.25-3.30
New out last night SRNE..Sorrento..9.43 Announced the presentation of preliminary results from ongoing Sars-Covid-19 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical deveopment for treatment of patients with Covid-19
One to watch GHSI..Health Science..Up 25% Tuesday .7999 Short term assets exceed Short and Long term liabilities Assets 12 million Debt 470K Revenue growth 2020 195%..US Drug Market Average 42% On Bullish Trend
Pre-market DARE..Clinical stage Bio-Pharm focused on Women's reproductive health Up 55%..3.65 Float 35 million Investor Observer 96 out of 100 Tip Ranks Strong Buy with Median Target Price 7.17
Pre-market LCTX..Up 45%..3.65 Bio-Tech ..Therapies for degenerative diseases.. Investor Observer..92 out of 100 Cash 38 million...Cash Burn 19 million Short term assets exceeds Short and Long term liabilites Assets 103 million Debt 2 million StockTA Very Bullish Long and Short A Barchart Strong Buy ..With 1 Hold and 4 Buys
Down pre-market but Bullish Long PERI..Perion Network is a Tech Company..Closed 13.96 a little dip this morning News out late yesterday preliminary review projects exceeding 2020 4th quarter expectations Stock expected to rise 113% over the next three months 408 million Market Cap..Low Float of 18 million Short term assets exceed Short and Long term liabilities Generating higher return on assets than Market average Debt 44 million Assets 321 millionTarget Price 25.00-34.00 Zacks 2 Buy..StockTA Very Bullish Long and A Barchart Strong Buy..2 Strong Buy..1 Moderate Buy and 1 Hold
